Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Top
Topic: Primary Sarcomas of Bone and Soft-tissue Metastatic

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 30 Nov 2022

Guest Editor(s)

  • Santiago A. Lozano Calderón, MD, PhD
    Department of Orthopaedic Surgery, Musculoskeletal Oncology Service, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

    Website | E-mail

Special Issue Introduction

Primary bone sarcoma and soft tissue sarcomas are rare neoplasms. Overall, bone sarcomas represent 0.2% of all malignancies, whereas soft tissue sarcomas account for 1% of all malignancies in the US. The most common bone sarcoma in adults is Osteosarcoma, followed by Chondrosarcoma, while in children, Ewing Sarcoma follows Osteosarcoma in prevalence. For soft tissue sarcomas, the most common and prevalent histologies include undifferentiated pleomorphic sarcoma (UPS), Liposarcoma, and Leiomyosarcoma. In general, males are more commonly affected than females. Most patients present with localized disease, but both bone and soft tissue sarcomas have the potential to metastasize primarily to the lungs, bone, liver, and in certain histologic subtypes to the lymphatic nodes.

This special issue will focus on the different aspects, techniques, and strategies to manage metastatic and oligometastatic primary bone and soft tissue sarcomas. We are considering pharmacologic, immunotherapeutic, surgical, and radiation approaches for treatment. Target topics include but are not limited to:
- Management of metastatic and oligometastatic disease in Osteosarcoma, Chondrosarcoma, Ewing Sarcoma, and other primary bone sarcomas
- Management of metastatic and oligometastatic disease in Soft Tissue Sarcomas
- Traditional chemotherapy
- Targeted therapies
- Immunotherapy
- Radiofrequency ablation and cryoablation
- Radiation protocols for palliative radiation and definitive treatment of metastasis with radiation therapy
- Surgical management of metastatic disease secondary to sarcoma

Participants:
1. Eduardo Ortiz Cruz, MD. Hospital Universitario la Paz, Madrid, Spain
2. Jose Ignacio Albergo, MD. Hospital Italiano, Bueno Aires, Argentina
3. Adam Levin, MD. Johns Hopkins University Hospital, Baltimore, Maryland, USA
4. Brooke Crawford, MD. University of Miami, Miller School of Medicine Cancer Center, Miami, Florida, USA
5. Ashok Muniappan, MD. Massachusetts General Hospital Cancer Center
Harvard Medical School, Boston, Massachusetts, USA

Submission Deadline

30 Nov 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=jcmt&SpecialIssueId=jcmt20220628
Submission Deadline: 30 Nov 2022
Contacts: Ivory Ma, Assistant Editor, ivory@jcmtjournal.com

Published Articles

none
© 2016-2022 OAE Publishing Inc., except certain content provided by third parties